



Introduction the pipeline embolization device (PeD) is 
a new endovascular stent designed for the treatment of 
challenging intracranial aneurysms (iAs). its use has been 
extended to nonruptured and ruptured iAs of a variety of 
configurations and etiologies in both the anterior and pos-
terior circulations.
Methods we conducted a systematic review of ten eligible 
reports on its clinical efficacy and safety.
Results there were 414 patients with 448 iAs. the major-
ity of the iAs were large (40.2 %), saccular or blister-like 
(78.3 %), and were located mostly in the anterior circula-
tion (83.5 %). the regimens of antiplatelet therapy varied 
greatly between and within studies. the mean number of 
the PeD used was 2.0 per iA. Deployment was successful 
in around 95 % of procedures. Aneurysm obliteration was 
achieved in 82.9 % of iAs at 6-month. the overall inci-
dences of periprocedural intracranial vascular complication 
rate and mortality rate were 6.3 and 1.5 %, respectively.
Conclusion the PeD is a safe and effective treatment for 
nonruptured iAs. its use in the context of acute subarach-
noid hemorrhage (SAH) should be cautioned. its main 
limitations include the need for prolonged antiplatelet 
therapy, as well as the potential risks of iA rupture and 
non-iA-related intracerebral hemorrhages (icH). Future 
studies should aim at identifying factors that predispose to 
incomplete obliteration, delayed rupture, and thromboem-
bolic complications.
Keywords cerebral aneurysm · endovascular treatment · 
Flow diverter · Pipeline embolization device
Introduction
Endovascular treatment (EVT) has significantly changed the 
treatment paradigm of intracranial aneurysms (iAs). endo-
saccular embolization with or without device assistance is 
now a widely adopted treatment modality [1, 2]. However, 
a subgroup of lesions, including fusiform [3], wide-necked 
[4], and large-to-giant aneurysms [5], continues to pres-
ent with major challenges. Many of these aneurysms have 
configurations that are unsuitable or unsafe for emboliza-
tion and/or conventional stenting. Recently, an alternative 
approach of endoluminal treatment has been developed for 
these lesions [6]. It involves the use of flow diverters that 
can disrupt the pulsatile blood flow within an aneurysm sac 
to the point of stagnation and thrombosis while maintaining 
flow in the parent artery and side branches. These devices 
may also facilitate neointimal regrowth and remodeling of 
the arterial wall. the initial clinical experiences were prom-
ising [7–9].
the pipeline embolization device (PeD; covidien 
Vascular Therapies, Mansfield, MA, USA) is one of the 
commercially available flow diverters [10]. it is a microcath-
eter-delivered, self-expanding, cylindrical stent composed 
of a mesh of 48 individual cobalt chromium and platinum 
strands. initially, approved for the treatment of iAs situated 
between the petrous and the superior hypophyseal segments 
of the internal carotid artery, its use has now been extended 
to lesions of various configurations and etiologies in both 
the anterior and posterior circulations. we present here a 
systematic literature review on the applications, safety, and 
clinical efficacy of this therapy.
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Methods
Search Strategy
the MeDliNe database was searched for all related arti-
cles published in the english language using the following 
keywords: “aneurysm”, “pipeline embolization device”, and 
“flow diverters”. These keywords were queried individually 
or in association. Abstracts were screened for eligibility, 
and the reference lists of eligible articles were searched for 
other related studies including on-line documents. the date 
of the last search was March 21, 2012. we included stud-
ies that described the clinical and angiographic outcomes 
of the PeD being used alone or in combination with other 
modalities. Only reports that consisted of five subjects or 
more were included. Reports with fewer than five subjects 
were referred to in the “Discussion” when appropriate.
Data collection and Analysis
The selection of articles and the evaluation of study quali-
ties were performed independently by two authors (Gilberto 
Ka Kit leung and Anderson chun On tsang). there was no 
disagreement. The system classification proposed by Cook 
et al. [11] was used to analyze the level of evidence. Data 
extracted from the eligible studies included the following: 
characteristics of the iAs (morphology, size, location, clini-
cal presentation, recent rupture, and previous treatment), 
treatment procedure (antiplatelet and anticoagulating thera-
pies, technical problems during deployment, the number of 
PeDs used, and adjuvant coiling), symptomatic procedure-
related complication and mortality, aneurysm obliteration 
and recanalization, in-stent stenosis and migration, as well 
as functional and symptomatic outcomes. we also studied 
iAs that had received previous stenting as a subgroup. the 
procedure for the deployment of the PeD was standardized 
and would not be further elaborated here.
Results
Description of Studies
there were ten eligible articles, including seven prospec-
tive single-arm cohort studies [9, 12–17], two retrospective 
uncontrolled case series [18, 19], and one ongoing random-
ized controlled open-label trial [20]. All completed stud-
ies were classified as Level V (“data from anecdotal case 
series”). Some of the subjects from two eligible studies were 
also involved in the PeD for the intracranial treatment of 
Aneurysms (PitA) trial [16]. the latter was an international 
multicenter study on 31 subjects from four centers. Six of 
the 63 iAs reported by lylyk et al. [9], and eight of the 19 by 
Szikora et al. [17] were included in the PitA report. How-
ever, the available information did not enable us to separate 
out these 14 overlapping subjects. we therefore conducted 
the review based on the total number of iAs reported instead 
of the actual number of iAs treated. the PipelinetM for 
Uncoilable or Failed Aneurysms Study (PUFS) [12], and 
the complete Occlusion of coilable Aneurysms (cOcOA) 
clinical Study [20] were conducted under an approved 
investigational device exemptions (iDe) application of the 
Food and Drug Administration (FDA), and were available 
as on-line reports.
we have excluded the report by Deutschmann et al. [21] 
in which all 12 patients were already included in the PitA 
report. the report by Puffer et al. [22] only studied specifi-
cally the patency of the ophthalmic artery after treatment 
and was also excluded. As mentioned, we have excluded 
reports that described fewer than five subjects [7, 23–38].
characteristics of Aneurysms
there were 414 patients with 448 iAs, including 374 
(83.5 %) and 74 (16.5 %) in the anterior and posterior cir-
culations, respectively. there were 351 (78.3 %) saccular 
or blister-like, 69 (15.4 %) fusiform, and 28 (6.3 %) dis-
secting iAs. All except two studies included a mixture of 
saccular and dissecting/fusiform iAs [18, 20]. Based on 387 
iAs with available information, the mean iA size was cal-
culated to be 12.0 mm. the lowest mean iA size per study 
was 3.8 mm, and the largest was 18.2 mm. there were 171 
(38.9 %) small (< 10 mm), 177 (40.2 %) large (10–25 mm), 
and 53 (12.1 %) giant (> 25 mm) iAs. the remaining 46 
(10.3 %) cases included 38 dissecting iAs and eight saccu-
lar iAs which the authors did not further categorize by size 
[18]. Based on seven studies that described clinical presen-
tations (n = 301), the majority of the iAs was asymptomatic 
(n = 152 or 50.1 %), followed by the presence of mass effect 
and cranial nerve palsies (n = 51 or 16.9 %). Sixteen (3.6 %) 
iAs were treated soon after acute subarachnoid hemorrhages 
(SAHs). Another 37 (8.3 %) iAs had previously ruptured 
but were not treated in the context of acute SAH. Prior to the 
placement of the PeD, 125 (27.9 %) lesions had received 
other treatments such as surgical clipping, coiling, and/or 
stenting (table 1).
Antiplatelet and Anticoagulating therapies
the regimens of antiplatelet therapy and heparinization var-
ied between and within studies. One study did not describe 
these in details [16]. Before surgery, all patients received 
aspirin and clopidogrel. these may be started at least 1 day 
[13, 19], 2 days [15, 17], 3 days [9, 18], 5 days [13, 15], or 
7 days [12] prior to surgery. the dosage of aspirin ranged 
from 100 to 150 mg, and that of clopidogrel from 75 to 
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600 mg. Point-of-care platelet inhibition tests were used in 
some centers [15, 19]. Heparinization was used to achieve 
an activated clotting time of more than 200 s. this was 
continued for at least 24 h post-operatively, except in one 
study in which heparinization was stopped by the end of the 
procedure [17]. After surgery, dual antiplatelet agents were 
continued for at least 3 months although aspirin was com-
monly continued for another 3 months [9, 12, 18] or even 
life-long [14]. Six months of dual agents may be used when 
the PeD was covering a side branch [13]. the duration of 
treatment may also depend on whether the iA affected the 
anterior (6 months) or the posterior (12 months) circulation 
[14, 15].
PeD Placement (tables 1 and 2)
More than 811 devices were used to treat 448 iAs; the exact 
number was not available in one study [19]. Based on the 
remaining nine studies, the mean number of PeD used was 
2.0 per iA. the mean number of PeD used per study ranged 
from 1.0 to 3.2 for each iA. Only one study did not employ 
multiple devices at all [13]. Fifty-four lesions were treated 
with adjuvant coiling. technical problems, including failed 
and suboptimal deployment, occurred during 23 procedures 
(5.1 %).
Procedure-Related complications and Mortalities (table 2)
we have included complications that were deemed to be 
procedure-related by the authors of the eligible studies. in 
analyzing the PUFS, which had an elaborate protocol guid-
ing the reporting of adverse events, we only included those 
complications defined under the study’s “primary safety 
endpoint” (i.e., the occurrence of major ipsilateral stroke or 
neurologic death by 180 days after treatment) [12]. From all 
ten studies, there were three cases of iA ruptures, 14 isch-
emic events, 11 non-iA-related intracranial hemorrhages, 
six cases of worsening of mass effect, 11 femoral or ret-
roperitoneal hematomas, and one fatal event of unknown 
nature. this yielded an overall symptomatic complication 
rate of 10.3 % (n = 46) for 447 iAs. if only intracranial vas-
cular (i.e., ischemic or hemorrhagic) events were included, 
the complication rate was 6.3 % (n = 28). Procedure-related 
mortalities occurred in nine (2.2 %) of the 413 patients. the 
causes of death were due to rebleedings from recently rup-
tured iAs (two cases) [14], bleeding from previously non-
ruptured iAs (two cases) [17, 19], ipsilateral intracranial 
hemorrhage not related to iA (three cases) [12, 20], delayed 
arterial thrombosis (one case) [19], and one neurologic 
event of unknown nature [12]. when only previously non-
ruptured iAs were analyzed (n = 394), the major intracra-
nial vascular complication and mortality rates were 6.1 and 
0.8 %, respectively. For iAs treated in the context of recent 
SAH (n = 16), the major intracranial vascular complication 
and mortality rates were 18.8 and 12.5 %, respectively.
Angiographic and clinical Outcomes (table 2)
Follow-up arrangements varied between and within studies. 
eight studies reported angiographic follow-up at 6-month 
or beyond for a total of 354 iAs. complete obliteration was 
achieved in 293 (82.8 %) lesions. Another study had follow-
up durations ranging from 2 to 6 months, and reported an 
obliteration rate of 84 % [13]. we also looked at 50 iAs 
that had previously been treated with conventional stenting. 
One study treated 30 iAs of these but it was not clear how 
many had follow-up angiography. the observed oblitera-
tion rate was stated as 65 % by the author [19]. Based on 
the assumption that all had follow-up angiographies, the 
obliteration rate for this subgroup was 68 % (or 34 in 50 
iAs; table 3). in-stent stenosis or thrombosis on angiograms 
occurred in 21 cases. Recanalization was uncommon (two 
cases) although few studies conducted longitudinal follow-
up angiographic studies after confirmed obliteration [12].
Five studies reported clinical outcomes using various 
parameters. Neurologic deterioration was uncommon among 
survivors [12]. the majority of patients were asymptomatic 
and well before surgery and had remained so afterward 
[9, 12, 13, 18]. in one study, symptomatic improvement was 
reported in 50 % of those with headaches, and in all patients 
presented with mass effects from their iAs [17].
Fifty iAs were treated with stenting prior to PeD place-
ment. complete obliterations occurred in 34 (68 %). intra-
cranial vascular complications occurred in five (10 %) of 
these 50 lesions, compared with 22 (5.6 %) in 390 lesions 
without previous stenting (table 3).
Discussion
the PeD
Currently, there are two main flow diverters commercially 
available for use, namely the PED and the SILK flow divert-
ers (SFD, Balt extrusion, Montmorency, France) [39]. 
Based on two recent reports, the SilK could achieve a simi-
lar iA obliteration rate as the PeD (around 80 %); the for-
mer, however, appeared to be associated with a higher early 
complication rate of around 17 % [40, 41]. Reported studies 
on SilK are too few to allow for a side-by-side comparison, 
and we focused only on the PeD in the present review. the 
PeD is designed to address several critical problems in the 
evt of iAs [2]. with coil embolization, reconstitution of 
the iAs may occur due to coil compaction. catheterization 
of the iAs may potentially cause rupture, and wide-necked 
1 3
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iAs may not hold the coils in place despite the use of stent 
assistance or balloon assistance [42]. the coils also form a 
permanent mass in the iAs that may potentially worsen any 
preexisting mass effect. with the PeD, there is no manipu-
lation within the iAs, and adjuvant coiling is not necessary 
though feasible. the PeD also has other theoretical advan-
tages. the device forms a scaffold upon which endothe-
lial regrowth can occur, leading to the full coverage of the 
implant and the aneurysm neck. when compared with self-
expanding or balloon-expandable stents, the PeD has higher 
metal surface area coverage, which greatly facilitates the 
occlusion of the aneurysm neck and neointimal regrowth. 
However, the degree to which this neointimal remodel-
ing occurs is unknown, and very late in-stent thrombosis 
has been known to occur [29]. ideally, the thrombotic clot 
within the iAs is reabsorbed by normal healing processes, 
leading to shrinkage of the iAs, a reduction of mass effect, 
and a potentially lower risk of recanalization. But even 
under highly controlled experimental conditions, complete 
obliteration is by no means the rule [10], and as discussed in 
the following section, the PeD may actually worsen preex-
isting mass effect. Because of the PED’s porosity, outflow 
in perforators and side branches can be maintained although 
long-term follow-up data are lacking [10]. Puffer et al. [22] 
studied the treatment of 20 paraclinoid iAs, and reported 
that in fact up to a quarter of ophthalmic arteries would 
undergo proximal thrombosis when covered with the PeD. 
Moreover, whether the PeD would be effective for bifur-
cation iAs or well tolerated in the presence of preexisting 
perforator stenosis is still unknown.
Based on the reviewed studies, the PeD was used mostly 
for the treatment of iAs that had failed or were considered 
unsuitable for conventional endosaccular embolization or 
endoluminal stenting. the majority of the lesions were large, 
asymptomatic, and saccular iAs situated in the anterior cir-
culation. the need for endoluminal coverage for these rela-
tively large-sized lesions may account for the large number 
of multiple devices used. experiences with the PeD in the 
treatment of dissecting iAs were comparatively limited. 
the available data did not allow a subgroup analysis, which 
would have been of interest given the different natural histo-
ries between saccular and dissecting iAs [14, 15, 18, 19]. De 
Barros Faria et al. [18] treated 23 dissecting aneurysms with 
the PeD and reported an overall occlusion rate of 87.5 %. 
Good clinical outcome was achieved in 74 % of patients . 
individual case reports have also described the successful 
use of the PeD for nonruptured [38] and ruptured [35] dis-
secting aneurysms. Further studies are needed to investigate 
the safety and efficacy of this particular application.
Procedure-Related complications
Fargen et al. [43] have recently reviewed complications 
associated with the PeD in the treatment of 374 nonruptured 
iAs. it reported a major complication rate and a mortality 
rate of 5.3 and 1.3 %, respectively. Our review included 
three additional studies and yielded similar findings. We 
also included iAs that were treated in the context of acute 
SAH which is still a matter of controversy [14, 34, 35]. After 
PeD placement, healing of the iAs is delayed while the pro-
cedure itself requires antiplatelet and anticoagulating thera-
pies, which can be problematic in the event of a rerupture. 
we found that two of the 16 recently ruptured iAs rebled 
soon after treatment and resulted in mortalities. Both rerup-
tured iAs were situated in the anterior circulation while all 
posterior circulation lesions were treated successfully. the 
complication and mortality rates for this subgroup were 
considerably higher than those of nonruptured iAs, but this 
may partly be due to the small number of cases involved. 
McAuliffe and wenderoth [14] suggested the use of adju-
vant coiling to secure the aneurysm fundus first, followed 
by PeD placement and the completion of coiling. However, 
balloon-assisted coiling may not be technically feasible for 
iAs that incorporate much of the wall of the native vessels 
for which the PED was indicated in the first place. In any 
case, there is at present not enough evidence to support the 
routine use of the PeD in the context of a recent rupture. the 
concern for PeD-induced rupture is further heightened by 
reports of delayed hemorrhages from otherwise silent iAs 
following PeD placement [23, 31, 37]. in our review, we 
found that two of the four post-PeD ruptures involved pre-
viously nonruptured iAs. the underlying mechanism was 
unclear. Mural destabilization and hemodynamic alteration 
from a PeD have been proposed as possible causes [31, 43]. 
Similarly, delayed ruptures have been reported with the 
Table 3 Outcome of aneurysms with previous stenting











McAuliffe et al. 
[15]
6  3 0
McAuliffe and 
wenderoth [14]
2  2 0
Fischer et al. [19] 30 20a 2 ischemic 
infarctions;  
2 icHs
Nelson et al. [17] 2  1 1 ischemic 
infarction
De Barros Faria  
et al. [18]
3  2 0
lylyk et al. [9] 7  6 0
total 50 34 5
IA intracranial aneurysm, ICH intracerebral hemorrhage, 
PED pipeline embolization device
aAssuming all patients had follow-up angiographies
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SilK diverter [33]. to our knowledge, no predisposing fac-
tors have been identified. At present, the small number of 
ruptured cases precluded meaningful risk analysis.
there were also 11 non-iA-related hemorrhagic com-
plications. the majority (n = 7) were intracerebral hemor-
rhages (icH) adjacent to or within the dependent territories 
of the treated arterial segments [12, 13, 16, 19, 20]. this 
yielded an incidence of 1.6 % for non-iA-related icHs 
within the anterior circulation. the underlying mechanisms 
were likely to be heterogeneous. Post-PeD hemodynamic 
alterations and hemorrhagic transformation of ischemic 
infarctions were possible explanations. in addition, iAs 
with previous stenting had a high rate of vascular complica-
tions, possibly due to compromised maneuverability during 
PeD deployment. As with intraluminal stents, thromboem-
bolism is a serious concern after PeD placement. Although 
the use of antiplatelet therapy was universal, the regimens 
varied greatly in details. Hyporesponsiveness to antiplate-
let therapy is a well-recognized phenomenon, and may be 
associated with coronary stent thrombosis [44] as well as 
thromboembolic complications during iA embolization 
[45]. Only a few centers used point-of-care platelet function 
tests although whether high on-treatment platelet activity 
contributed to the occurrence of ischemic complications is 
difficult to ascertain [46]. interestingly, one study that used 
point-of-care tests also reported a high incidence of tran-
sient ischemic attack but this may be due to an increased 
alertness and detection bias [15].
the worsening of preexisting mass effects is an interest-
ing finding in that, unless adjuvant coiling is used, the PED 
does not result in a coil mass and the iAs are supposed to 
shrink following treatment. lylyk et al. [9] treated three 
giant iAs that were causing cranial nerve palsies, and all 
had postoperative deteriorations despite steroids cover. All 
eventually improved. McAuliffe et al. [15] treated 16 iAs 
that were causing mass effects before surgery. the sizes of 
the lesions were not reported. eight received steroids cover 
and three experienced worsening of symptoms. How many 
of these cases involved coiling was not clear. Inflammatory 
responses secondary to endosaccular thrombosis were likely 
to be responsible. conversely, Szikora et al. [17] treated six 
iAs with mass effects and all improved after surgery. these 
findings highlight the importance of collecting solid clinical 
evidence to support the theoretical advantages of the PeD.
Aneurysm Obliteration and Recanalization
the mechanism of action of the PeD does not depend on 
the size, the configuration, or the dense packing of the aneu-
rysm sac. it is therefore particularly effective for the treat-
ment of some of the challenging iAs. we found an overall 
obliteration rate of more than 80 % at 6-month, which 
compares favorably with that of stent-assisted [47] or bal-
loon-assisted embolization [48]. Recanalization was also 
uncommon although there were very few follow-up stud-
ies after confirmed obliterations. The IAs in the reviewed 
series were too heterogeneous and the available informa-
tion not comprehensive enough to allow the identification 
of predisposing features of incomplete occlusion. we did, 
however, found a lower obliteration rate in iAs that had pre-
viously undergone stenting procedures. Several authorities 
suggested that the presence of a stent may reduce the chance 
of PeD-induced obliteration by complicating deployment, 
impairing the apposition of the stent to the arterial wall and 
disrupting neointimal remodeling [9, 16]. this should be 
taken into considerations during treatment planning for iAs 
that are potentially suitable for the PeD.
limitations of Study
it must be emphasized that the majority of the reviewed 
studies were self-adjudicated single-center studies with 
varied, relatively short or incomplete follow-ups. this may 
potentially result in underestimations of the overall compli-
cation rate as well as the number of eventual recoveries from 
initially unfavorable outcomes. For instance, in the PUFS, 
some cases of hemorrhagic complications did not reach pri-
mary endpoints and were therefore not included in our anal-
ysis. Both the PUFS and COCOA reports consisted of only 
on-line documents based on a company-driven registry, and 
their results should be considered with care [12]. Further-
more, two studies had patients that overlapped with those 
in the PitA which may affect the accuracy of our analysis.
Conclusions
the PeD is a feasible, effective, and safe method for the 
endoluminal treatment of nonruptured iAs. its use in the treat-
ment of recently ruptured iAs is associated with a relatively 
high rate of rebleeding and should be cautioned. Previous 
stenting may also result in poorer outcome. Recanalization 
after complete obliteration, in-stent stenosis and thrombosis 
are uncommon. the main limitations of the PeD include 
the need for prolonged antiplatelet therapy, and the poten-
tial risks of delayed rupture, non-iA-related icH, worsening 
of preexisting mass effect, and reduced efficacy with previ-
ous stenting. Flow-diverting devices represent an important 
advancement in the treatment of iAs although many of the 
theoretical advantages of the PeD such as aneurysm shrink-
age and neointimal remodeling are yet to be proven experi-
mentally or clinically. Randomized studies comparing the 
PED with conventional EVT are methodologically difficult 
since each modality has its unique indications in terms of IA 
characteristics. Future studies may aim at identifying fac-
1 3
302 G. K. K. leung et al.
tors that predispose to incomplete occlusion, PeD-induced 
rupture, and thromboembolic complications.
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